Fulgent Genetics (FLGT) Cash & Current Investments (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Cash & Current Investments data on file, last reported at $276.3 million in Q1 2026.

• Quarterly Cash & Current Investments fell 13.74% year-over-year to $276.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.3 million (down 13.74% YoY) and the FY2025 annual result came in at $336.1 million, up 30.21% from the prior year.
• Cash & Current Investments fell to $276.3 million in Q1 2026 per FLGT's latest filing, from $336.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $585.1 million in Q1 2022, with the low at $213.1 million in Q3 2024.
• Average Cash & Current Investments over 5 years is $385.3 million, with a median of $375.8 million recorded in 2025.
• Year-over-year, Cash & Current Investments surged 87.02% in 2022 and slumped 54.45% in 2024.
• Fulgent Genetics' Cash & Current Investments stood at $526.2 million in 2022, then declined by 19.4% to $424.2 million in 2023, then plunged by 39.15% to $258.1 million in 2024, then surged by 30.21% to $336.1 million in 2025, then fell by 17.79% to $276.3 million in 2026.
• Business Quant data shows FLGT's Cash & Current Investments at $276.3 million in Q1 2026, $336.1 million in Q4 2025, and $375.8 million in Q3 2025.